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Case
A 45-year-old male with a history of human immunodeficiency 
virus, (HIV), on highly active antiretroviral therapy (HAART), 
Kaposi’s sarcoma, and squamous cell carcinoma (SCC) of the 
right lower extremity complicated by chronic wound formation 
presented with worsening right leg pain and increasing wound 
drainage. 
The patient described the pain as excruciating, with 10/10 
intensity and exacerbated by movement. His wounds began 
draining purulent material and blood about two weeks prior to 
presentation. He has had several similar, though milder episodes 
in the past requiring hospitalization. When the wounds began 
to have a foul odor, he presented to the hospital. On review of 
systems, the patient reported new-onset back pain that began 
approximately one week prior to admission. The pain was 
constant, sharp, worse with movement, and had an insidious 
onset. He also had a recent 30 lb weight loss with worsening 
fatigue. He denied fevers and chills.
His medical history included HIV and Kaposi’s sarcoma in the 
right groin, both diagnosed concomitantly five years ago. Soon 
after diagnosis he had been started on HAART, and underwent 
chemotherapy with paclitaxel and liposomal doxorubicin. He 
subsequently developed multiple wounds spreading over his 
right leg. These became complicated by recurrent infections with 
methicillin resistant Staphylococcus aureus (MRSA) requiring 
surgical debridement and intravenous antibiotics. Two months 
prior to admission his wounds were biopsied and pathology 
revealed a poorly differentiated SCC. He continued to undergo 
wound management as an outpatient while plans were made to 
reevaluate his new malignancy. His medications on admission 
included Atripla, hydromorphone, fluconazole, TMP-SMX, 
omeprazole, ondansetron, and ibuprofen.
The patient lived at home with his same sex partner. He worked 
in the restaurant business before becoming disabled. He had 
recently quit smoking but has a 20 pack year history, a remote 
history of cocaine abuse, and was a social alcohol consumer. His 
family history was notable for diabetes and hypertension.
On physical exam, the patient’s vital signs were all within 
normal limits. He was a frail man with temporal wasting. He 
was in no acute distress and was alert and oriented. His mucous 
membranes were dry without evidence of thrush. He had no 
cervical or supraclavicular lymphadenopathy. His cardio-
vascular, pulmonary, and abdominal exams were unremarkable. 
There was diffuse tenderness to palpation over the thoracic and 
lumbar spine. On his right lower extremity there were confluent, 
raised, macerated tumors, extending from the knee to ankle, with 
involvement of his plantar foot, 2nd, and 3rd digits (Figure 1). A 
foul smelling, sero-sanguinous drainage was observed emanating 
from these growths.
On admission, laboratory studies were notable for a white 
blood cell count of 11.1x109/L, hemoglobin of 7.8 mg/dL, 
platelets of 409 x 109/L. Serum chemistry was notable for 
sodium of 127 mmol/L. His CD4 count was 208 cells/uL and 
HIV viral load was 14,400 IU/mL. A computed tomography 
(CT) scan of the chest, abdomen and pelvis revealed mural 
thickening throughout the entire esophagus and proximal 
stomach, retroperitoneal lymphadenopathy, and a pathologic 
compression fracture at the level of L2. An magnetic resonance 
imaging (MRI) of the right lower extremity demonstrated 
innumerable subcutaneous fluid collections in the right leg, 
with abscess formation in the antero-medial aspect of the 
proximal leg eroding into the tibial cortex. There was diffuse 
nodular skin thickening with enhancement around his tumors 
(Figure 2). Wound cultures from his leg grew MRSA and 
Pseudomonas aeruginosa.
Hospital Course
The patient required numerous packed red blood cells 
transfusions, intravenous antibiotics, and aggressive wound care. 
He underwent CT-guided biopsy of the pathologic lumbar spine 
fractures. The pathology from these specimens was consistent 
with metastatic SCC. The patient was seen in consultation by 
surgery, medical oncology, radiation oncology, gastroenterology 
and infectious disease. He was offered amputation of his leg, but 
adamantly declined this option. He opted instead for a course of 
palliative chemotherapy. 
Discussion
Infection with HIV has long been known to increase the risk 
of developing cancer. Classically these cancers are included 
in the category of AIDS-defining illnesses, and are found in 
patients with poor viral suppression. Among the well known 
examples are Kaposi’s sarcoma, primary central nervous system 
lymphoma, non-Hodgkin’s lymphoma, and invasive cervical 
cancer. Mainstays of therapy for these malignancies have 
always included HAART. The improved use and delivery of 
HAART has prolonged the lifespan of HIV-infected patients. 
In the post-HAART era there has been an increasing incidence 
of non-AIDS-defining malignancies (NADM). These NADMs 
have emerged as an important cause of morbidity and mortality 
in the HIV-infected population.1-3
Since the mid-1990s the estimated number of AIDS-defining 
cancers has decreased by greater than threefold, whereas the 
number of NADMs has increased by approximately threefold.5 
This increased incidence is partly a result of improved screening 
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and diagnostic modalities for cancer, as well as patient longevity 
and increased prevalence of HIV infection. However, NADMs, 
after correcting for risk factors, have occurred in higher 
incidences than in the general population, despite appropriate 
viral suppression.1,4-6 One study by the American Cancer Society 
showed that in the HIV population the rates of developing 
NADMs within the United States was more than double that 
of the general population, with a rate of 980 new NADMs per 
100,000 person-years.7
The traditional risk factors for cancer, such as genetics and 
carcinogen exposure, apply to patients with HIV-infection. 
Incidence does not increase with low CD4 nadirs.7 NADMs 
typically have a far more aggressive course than similar 
malignancies in the general population. The exact mechanisms 
responsible for the increased incidence and worse clinical course 
of these malignancies in the HIV population remains unclear.3,7 
CD4 lymphopenia, cell mediated immune dysfunction, 
change in cytokine profile and role of HIV proteins, have 
all been postulated to play a role in tumor development.10 
Immunosuppression without CD4 depletion may also play a 
role. This has been demonstrated by studies comparing organ 
transplant recipients to the HIV population, both of whom 
share a similar profile of cancer types and rates of occurence.8
A number of specific NADMs have been identified as having 
increased incidence with HIV infection. These include anal 
cancer, Hodgkin’s disease, head and neck cancers, testicular 
cancer, prostate cancer, basal cell cancer, SCC of the skin, and 
melanoma.3,7 Among these cancers, the cutaneous NADMs are 
the most frequent, occurring at a rate of 6% in patients with HIV, 
supplanting Kaposi’s sarcoma as the most common malignancy 
in this population.9
SCC has been demonstrated in multiple case studies to be highly 
aggressive in the setting of HIV. It presents at a significantly 
younger age than non-HIV patients (44 versus 70 years), has 
been associated with a high risk for local recurrence, metastasis, 
and has a 50% mortality risk.9-13 The major risk factors for 
developing skin cancer with concomitant HIV infection are 
mostly the same as in the general population, including fair-skin, 
family history, and sun exposure.14 More than half of patients 
diagnosed with SCC have a history of genital warts, suggesting 
a possible link with human papillomavirus (HPV) infection. 
However no direct link has yet been established between HPV 
infection and SCC in HIV patients.10,15
 The management of NADMs in patients with HIV can be 
challenging for a variety of reasons. Patients with HIV often have 
significant co-morbidities that can affect performance status 
and treatment options. Staging the cancer can also be unreliable 
in the setting of reactive lymphadenopathy typically found with 
HIV infection. Other concerns include the combined toxicity of 
chemotherapy and HAART, as well as the immunosupressive 
effects of chemotherapy in already high-risk patients. Despite 
these obstacles, management should involve an aggressive, 
multidimensional approach. Therapy should include HAART, 
regardless of CD4 counts.16 Choices for chemotherapy should be 
tailored to the patient and the tumor. Wide excisions with careful 
analysis of margins should be performed to avoid recurrence.10 
There should also be special attention to prophylaxis against 
opportunistic infections while administering treatment. 
Conclusion
Infection with HIV has long been associated with an increased 
risk of developing cancer. In the post-HAART era, there has 
been an increasing incidence of malignancies not classically 
included in the category of AIDS-defining illnesses. This is 
partly due to improved patient survival and cancer screening, 
but is also linked to HIV infection itself. Most of these cancers 
present at an earlier average age than in the general population, 
and are highly aggressive. Heightened screening vigilance is thus 
called for in the HIV population. Inclusion of HAART remains 
a cornerstone of management, as does a highly aggressive and 
multidisciplinary approach to managing the malignancy. 
The morbidity and mortality due to aggressive SCC is dependent 
on the initial control of the local or metastatic disease. Physicians 
treating SCC should ensure that their patients receive adequate 
resection with margin control. They should consider local or 
regional adjunctive radiation and/or chemotherapy as well as 
sentinel node procedures for high risk tumors. The initial CD4 
count does not alter the approach to these cancers. Primary 
prevention is essential to improved survival, so regular screening 
exams and early biopsies of suspicious lesions are strongly 
advocated.10
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Demons and Dreams
Mariam Kabir, MD
Demons aplenty
In my life of scanty dreams
Demons aplenty
Taking away my beams.
Once in a while
They scatter away
And I see the light of day.
Once in a while
They leave me alone
And I see what may.
Demons aplenty
In my head of limited space
Crowding out thoughts of joy
Whispering acrimonies
Fears and bitter hitters
Leading me to
Yearn their banishment
From my head 
Of limited space,
So I can see
Beams.
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